Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience

Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience

Objective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been proposed as a distinct subgroup. This study investig...

Full description

Saved in:

Bibliographic Details
Main Author:	ılkay Cinar
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605251342508
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Human Epidermal Growth Factor Receptor 2-Low Breast Cancer: Prevalence Rate and Scoring Concordance Among Pathologists
by: Maher Sughayer, et al.
Published: (2025-08-01)

Correlation analysis on epidermal growth factor receptor (EGFR) mutations and clinicopathological characteristics in lung adenocarcinomas
by: Haitao Wang, et al.
Published: (2025-03-01)

Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
by: Rashmi Patnayak, et al.
Published: (2015-01-01)

Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2
by: Jiayu Li, et al.
Published: (2021-01-01)

Trastuzumab: A milestone in human epidermal growth factor receptor 2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2020-01-01)

Trastuzumab emtansine for residual invasive human epidermal growth receptor-2-positive breast cancer
by: Joydeep Ghosh, et al.
Published: (2020-01-01)

A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
by: Yincheng Liu, et al.
Published: (2025-07-01)

Expression of hormone receptors and human epidermal growth Factor2/Neu in female breast cancer patients
by: Adrees U., et al.
Published: (2024-10-01)

Expression of human epidermal growth factor receptor 2 in meningiomas
by: Mazaher Ramezani, et al.
Published: (2020-01-01)

Prevalence and clinicopathological characteristics of breast cancer patients with brain metastases in Ghana: A single-center cross-sectional study.
by: Joseph Daniels, et al.
Published: (2025-01-01)

Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania
by: Lemi Ndugumbi Zinga, et al.
Published: (2025-08-01)

Protein expression of estrogen, progesterone, and human epidermal growth factor receptors in young Iraqi women with breast cancer
by: K. A. Al-Hilali, et al.
Published: (2024-10-01)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
by: Seema Gulia, et al.
Published: (2016-01-01)

Clinicopathological and Demographics Analysis of Testicular Tumors: A Single-center Experience
by: Yakup Düzköprü, et al.
Published: (2025-04-01)

Association of soluble urokinase plasminogen activator receptor and epidermal growth factor with histopathological findings of kidney biopsy: a single-center study
by: Eman Nagy, et al.
Published: (2025-07-01)

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
by: Kristine Astvatsaturyan, et al.
Published: (2018-01-01)

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
by: Huang-Chih Chang, et al.
Published: (2017-03-01)

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01)

The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients
by: Li Yingying, et al.
Published: (2025-07-01)

Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
by: Xinrui Dong, et al.
Published: (2022-01-01)

Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
by: Sandip Ganguly, et al.
Published: (2020-01-01)

Multi-sequence MRI-based nomogram for prediction of human epidermal growth factor receptor 2 expression in breast cancer
by: Mengyi Shen, et al.
Published: (2025-02-01)

Treatment challenges and survival analysis of human epidermal growth factor receptor 2-positive breast cancer in real world
by: Praveen Adusumilli, et al.
Published: (2017-01-01)

Distinguishing Low Expression Levels of Human Epidermal Growth Factor Receptor 2 in Breast Cancer: Insights from Qualitative and Quantitative Magnetic Resonance Imaging Analysis
by: Yiyuan Shen, et al.
Published: (2025-03-01)

Study on clinicopathological features and prognosis of HER2 low expression breast cancer
by: RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun
Published: (2024-10-01)

Clinicopathological features and outcomes of rare lung adenocarcinoma metastasis to the thyroid gland: A single‐center, 11‐year experience
by: Xuehan Gao, et al.
Published: (2025-01-01)

Antitumor effect of a new human epidermal growth factor receptor inhibitor
by: O. I. Kit, et al.
Published: (2024-09-01)

Expression of Human Epidermal Growth Factor Receptor (HER2/neu) and Proliferative Marker Ki-67 in Nonneoplastic, Preneoplastic, Neoplastic Lesions of Gallbladder and Its Association with Clinicopathological Parameters
by: Kiran Yadav, et al.
Published: (2025-01-01)

Intratumoral and peritumoral radiomics based on automated breast volume scanner for predicting human epidermal growth factor receptor 2 status
by: Hao Zhang, et al.
Published: (2025-04-01)

Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective
by: Gupta Sudeep, et al.
Published: (2018-01-01)

Molecular Docking Study: Application to the Epidermal Growth Factor Receptor
by: Faiza Asli, et al.
Published: (2024-11-01)

Cell Adhesion Molecules as Modulators of the Epidermal Growth Factor Receptor
by: Irina Kozlova, et al.
Published: (2024-11-01)

The status of epidermal growth factor receptor and topoisomerase IIα genes in triple-negative breast cancer cells
by: D. A. Karseladze, et al.
Published: (2014-08-01)

Programmed death 1 inhibitor combined with radiotherapy decreases epidermal growth factor receptor expression in breast cancer
by: You Wu
Published: (2025-08-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience
by: Neda Yaghoubi, et al.
Published: (2025-05-01)

Recent Trends in the Clinicopathological Features of Thyroid Nodules in Pediatric Patients: A Single Tertiary Center Experience over 25 Years
by: Cheong-Sil Rah, et al.
Published: (2019-01-01)

Clinicopathologic Spectrum of Xanthogranulomatous Pyelonephritis: A Single Center Experience over 8 Years
by: Farhat Abbas, et al.
Published: (2022-04-01)

Human epidermal growth factor receptor 2 expression and associated factors in endometrial carcinoma
by: Shiyun ZHANG, et al.
Published: (2025-06-01)

A Premature Termination of Human Epidermal Growth Factor Receptor Transcription in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2014-01-01)